Merit Medical Systems, Inc. (MMSI) reported third-quarter 2025 adjusted EPS of 92 cents, up 6.9% from the year-ago quarter, surpassing the Zacks Consensus Estimate by 12.2%. GAAP EPS was 46 cents, down 4.2% year over year.

Revenues for the quarter were $384.2 million, up 13% year over year, exceeding the Zacks Consensus Estimate by 3.5%. U.S. sales were $230.6 million, up 11.7%, while international sales were $153.6 million, up 15.2%.

In the Cardiovascular segment, revenues were $366.4 million, with Peripheral Intervention revenues at $144.8 million, Cardiac Intervention at $116.7 million, Custom Procedural Solutions at $54.1 million, and OEM at $50.8 million. Endoscopy segment revenues were $17.7 million.

Merit Medical’s gross profit increased 18.3% to $186.4 million, with a gross margin of 48.5%. Operating expenses rose, but adjusted operating profit increased to $42.6 million with an operating margin of 11.1%.

Exiting the quarter, Merit Medical had cash and cash equivalents of $392.5 million. Net cash provided by operating activities was $198.9 million. The company raised its outlook for 2025, with projected net revenues between $1.502 billion and $1.515 billion.

Merit Medical signed an agreement to acquire the C2 CryoBalloon device, expanded Embosphere Microspheres use in the EU, and released the Prelude Wave Hydrophilic Sheath Introducer. Challenges in the global macroeconomic environment remain a concern. The company has a Zacks Rank #2.

Other top-ranked stocks in the medical space are Boston Scientific Corporation (BSX), GE HealthCare Technologies Inc. (GEHC), and Intuitive Surgical, Inc. (ISRG), all reporting strong quarterly results and positive growth outlooks.

Read more at Nasdaq: Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand